March 1995

Halofuginone, A Specific Collagen Type I Inhibitor, Reduces Anastomotic Intimal Hyperplasia

Author Affiliations

From the Department of Surgery (Drs Choi and Brown), Washington University School of Medicine (Mr Sehgal), St Louis, Mo, and the Section of Vascular Surgery, the Department of Surgery (Dr Callow), and the Department of Medicine (Dr Ryan), Boston (Mass) University School of Medicine.

Arch Surg. 1995;130(3):257-261. doi:10.1001/archsurg.1995.01430030027004

Objective:  To determine if halofuginone hydrobromide, a specific type I collagen inhibitor, could prevent intimal hyperplasia at a vascular anastomosis.

Design:  Intimal hyperplasia is characterized by smooth muscle cell proliferation and extracellular matrix accumulation. Halofuginone was used to block collagen production and smooth muscle cell proliferation in cell cultures and in a rabbit model of an end-to-end anastomosis of the right common carotid artery. Animals were fed a nontoxic dose of halofuginone. Eighteen rabbits were fed the inhibitor in a randomized blinded fashion and were examined after 4 weeks by harvesting the arteries after perfusion fixation at physiologic pressures.

Results:  Halofuginone inhibited smooth muscle cell proliferation in vitro and had no effect on cell viability. Morphometric quantification verified that halofuginone treatment significantly attenuated anastomotic intimal thickness.

Conclusion:  Oral administration of halofuginone inhibits intimal hyperplasia at vascular anastomoses. Intimal hyperplasia inhibition by halofuginone may be a therapeutic option for preventing arterial stenosis in vascular surgery.(Arch Surg. 1995;130:257-261)